NutriBand quarterly revenue down, loss narrows
NutriBand reduced losses and cash burn in Q2 FY2027 despite a more than 30% year‑over‑year revenue decline driven by lower Pocono sales.
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
NutriBand Inc. (NTRB) reported lower revenue but narrower losses for the three and six months ended July 31, 2026. Revenue for the quarter was $437,514 versus $622,452 a year earlier, and six‑month revenue was $870,913 versus $1,289,884, primarily reflecting reduced sales at Pocono Pharmaceuticals after a principal customer moved operations to Asia.
Six‑month net loss improved to $2,122,517 from $3,389,206, helped by lower selling, general and administrative expenses and reduced research and development spending on the AVERSA Fentanyl program. Operating cash outflow fell to $1,148,103, and cash stood at $3,421,615 with working capital of $2,912,335, which management believes is sufficient to support operations for at least one year and alleviates prior going‑concern uncertainty. The company continues to invest in its AVERSA abuse‑deterrent transdermal pipeline and maintains a material weakness in internal control over <a href="https://bitcomme.com/el-paso-school-district-shares-financial-updates-and-concerns/” title=”El Paso school district shares financial updates and concerns”>financial reporting, despite some remediation efforts.
Positive
- Net loss for the six months improved to $2.1 million from $3.4 million, with operating cash outflow cut to $1.1 million from $2.7 million, indicating significantly lower cash burn.
- Management reports sufficient liquidity, with $3.4 million in cash and $2.9 million in working capital, and states that prior substantial doubt about going concern is alleviated based on its 12‑month outlook.
Negative
- Revenue declined more than 30%, to $870,913 for six months from $1,289,884, mainly due to a principal Pocono Pharmaceuticals customer moving operations to Asia and no current sales at 4P Therapeutics.
- The company still recorded a net loss of $2.1 million for six months and an accumulated deficit of $48.8 million, highlighting continued dependence on external financing and successful product development.
- Disclosure controls and internal control over financial reporting remain not effective due to material weaknesses, including limited segregation of duties and reliance on a small accounting staff.
